Mumps

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

UK Travel Vaccine Market Report 2022: Increasing Travel and Tourism & Growing Incidences of Infectious Diseases Fuel Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022

The "UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis By Product and Application" report has been added to ResearchAndMarkets.com's offering.
  • Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses.
  • Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others.
  • Based on application, the travel vaccine market is segmented into domestic travel and outbound travel.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Global Otoscopes Market Research Report 2022: Market to Reach $198.1 Million by 2026 - US and Europe Dominate the Market

Retrieved on: 
Wednesday, August 24, 2022

DUBLIN, Aug. 24, 2022 /PRNewswire/ -- The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 24, 2022 /PRNewswire/ -- The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Otoscopes estimated at US$172.8 Million in the year 2022, is projected to reach a revised size of US$198.1 Million by 2026, growing at a CAGR of 3.2% over the analysis period.
  • Pocket-size Otoscopes, one of the segments analyzed in the report, is projected to record a 2.9% CAGR and reach US$89.4 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $60.4 Million in 2022, While China is Forecast to Reach $14 Million by 2026
    The Otoscopes market in the U.S. is estimated at US$60.4 Million in the year 2022.

Global Otoscopes Market Research Report 2022: AI-Powered Otoscopy Makes Headway in the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, August 22, 2022

The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Otoscopes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • In the global Video Otoscopes segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment.
  • The market growth is also facilitated by availability of rechargeable, user-friendly pocket otoscopes along with increasing number of otolaryngology professionals.
  • Rising incidence of hearing loss is also expected to drive the global otoscopes market in the long-term.

EasiBuy to Exhibit at NIGP Forum 2022, Co-Founder Ben Koberna to Speak on Procurement Modernization

Retrieved on: 
Thursday, August 18, 2022

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    On Aug. 22, at 1:00 pm in The Innovation Theater, Koberna will present Procurement Mind Training, an interactive program designed to help professionals hone the leadership skills necessary to navigate the procurement modernization journey.
  • Koberna has been shaping the nature of reverse auction practice in the government setting since 2007.
  • EasiBuy will also be present throughout the event as an exhibitor and can be found at booth #625 in the events Exhibit Hall.
  • Forum 2022 will be held in Boston from Aug. 20-24 at the Boston Convention and Exhibition Center.

Illinois Residents Can Help Play Critical Role in Protecting Local Communities by Scheduling Immunizations

Retrieved on: 
Wednesday, August 17, 2022

Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.

Key Points: 
  • Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.
  • Amid the COVID-19 pandemic, immunizations have declined, with all populations showing a downward trend from pre-pandemic routine immunization rates .
  • Routine vaccinations have proven effective in preventing serious illness within schools and communities.
  • Immunizations not only protect the individuals who are vaccinated, they also protect everyone who interacts with them.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Retrieved on: 
Thursday, July 21, 2022

Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.
  • Of the 62 patients treated with HYQVIA, the majority of treatment-related adverse events were reported as mild or moderate.
  • ADVANCE-1 was a Phase 3, multicenter, placebo-controlled, double-blinded study to evaluate the efficacy, safety and tolerability of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as a maintenance therapy to prevent relapse in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
  • Some of the secondary endpoints included time to relapse, effect on activities of daily living (ADL), safety and tolerability.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.